Modified immunotoxins and monoclonal antibodies exhibit specific binding and endocytosis when targeting CD7 molecules, effectively inhibiting the growth of CD7-positive Jurkat and CEM cell lines, as well as T-ALL patient samples. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.